Intelligence · Patent portfolio
Regeneron Ireland Designated Patents
Full USPTO pharma patent portfolio for Regeneron Ireland Designated — grant dates, expiration, and drug cross-links.
- Patents
- 8,292
- Expiring ≤24m
- 426
Quick answer
Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months — use filters for patent-cliff planning.
-
US 12187848
Compositions and methods for cellular delivery
granted -
US 12186342
Autologous irradiated whole cell tumor vaccines lentivirally engineered to express CD80, IL-15 and IL-15 receptor alpha
granted -
US 12186384
Compositions and methods for making and using thermostable immunogenic formulations with increased compatibility of use as vaccines against one or more pathogens
granted -
US 12186314
Compositions and methods for treatment, amelioration, and prevention of anesthesia-induced hypothermia
granted -
US 12187992
Method and device for early cancer screening
granted -
US 12188949
Noninvasive method to quantify kidney function and functional decline
granted -
US 12186349
Compositions and methods for C. difficile treatment
granted -
US 12188039
Recombinant adeno-associated viral vector for gene delivery
granted -
US 12187777
Engineered invariant natural killer T (iNKT) cells and methods of making and using thereof
granted -
US 12188926
Stimuli responsive microsphere composites
granted -
US 12180503
Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
granted -
US 12180277
LILRB4-binding antibody and methods of use thereof
granted -
US 12180504
Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
granted -
US 12178787
T cell receptors for immunotherapy
granted -
US 12181555
3-dimensional representations of post-contrast enhanced brain lesions
granted -
US 12178887
NIR-conjugated tumor-specific antibodies and uses thereof
granted -
US 12179037
Radiotherapies and uses thereof
granted -
US 12178889
Gold nanoparticle-ligand conjugates and methods of use
granted -
US 12180300
Targeting moiety-drug grafted immune cell compositions and methods of use
granted -
US 12178868
Immunogenic compositions and uses thereof
granted -
US 12180084
Cerium (III) carbonate formulations
granted -
US 12180251
Nucleic acids encoding peptides that block binding of a2d-1 to glutamate receptors for treating diseases and disorders
granted -
US 12180509
Methods for reprograming non-pluripotent cells into pluripotent stem cells
granted -
US 12178848
Methods and compositions for the treatment of exocrine pancreatic insufficiency
granted -
US 12178417
Devices and methods for umbilical cord processing
granted -
US 12171786
Use of mesenchymal stem cells for the treatment of inflammation
granted -
US 12171877
Materials and methods for delivering compositions to selected tissues
granted -
US 12171884
Mesoporous silica nanoparticles with lipid bilayer coating for cargo delivery
granted -
US 12173061
Compositions and methods for treatment of chronic lung diseases
granted -
US 12173084
Phosphorylated dicer antibody and methods of use thereof
granted -
US 12173029
Antiviral prodrugs, pharmaceutical formulations, and methods
granted -
US 12173089
Inhibition of pulmonary fibrosis with nutlin-3A and peptides
granted -
US 12171734
Pathogenic bacteria
granted -
US 12173088
Anti-microbial peptides
granted -
US 12171785
Pluripotent cells derived from bone marrow and methods for isolation
granted -
US 12171803
Methods of CD40 and toll like receptor immune activation
granted -
US 12173087
Melanocortin 1 receptor ligands and methods of use
granted -
US 12173317
Use of histone modifiers to reprogram effector T cells
granted -
US 12168013
Antiviral prodrugs and nanoformulations thereof
granted -
US 12168056
Scintillator nanocrystal-containing compositions and methods for their use
granted -
US 12168691
VHS format bi-specific antibodies specific for HER2 and VEGF and use thereof
granted -
US 12168678
Heme sequesting peptides and uses therefor
granted -
US 12163168
Engineered primate cystine/cysteine degrading enzymes for therapeutic uses
granted -
US 12163148
Directed editing of cellular RNA via nuclear delivery of CRISPR/Cas9
granted -
US 12161618
Methods of identifying and treating patients with HIF-2 inhibitor resistance
granted -
US 12162870
Anticancer compounds
granted -
US 12161621
Methods for fructokinase mediation of alcohol craving and alcohol induced liver disease
granted -
US 12161648
Covalent targeting of E3 ligases
granted
Frequently asked questions
How many patents does Regeneron Ireland Designated have?
8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Regeneron Ireland Designated patents expire?
426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources · Patent directory